GSK plc Files 6-K on Share Transactions
Ticker: GLAXF · Form: 6-K · Filed: Sep 17, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Sep 17, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-transaction, 6-K, company-update
TL;DR
GSK plc filed a 6-K on 9/17/25 about share transactions.
AI Summary
GSK plc filed a Form 6-K on September 17, 2025, reporting a transaction in its own shares. The company, formerly known as GlaxoSmithKline PLC, is based in London and operates in the pharmaceutical preparations industry.
Why It Matters
This filing indicates GSK is actively managing its share capital, which can impact stock value and investor perception.
Risk Assessment
Risk Level: low — This is a routine filing reporting on share transactions, not indicating any new material risks.
Key Players & Entities
- GSK plc (company) — Registrant
- GlaxoSmithKline PLC (company) — Former company name
- September 2025 (date) — Reporting period
- 001-15170 (other) — Commission File Number
FAQ
What type of transaction is GSK plc reporting in this 6-K filing?
GSK plc is reporting a 'Transaction in own shares'.
What is the filing date of this Form 6-K?
The filing date is September 17, 2025.
What is GSK plc's principal executive office address?
GSK plc's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Has GSK plc previously operated under a different name?
Yes, GSK plc was formerly known as GlaxoSmithKline PLC, with a name change date of January 5, 2001.
Does GSK plc file annual reports under Form 20-F?
Yes, the filing indicates that the registrant files or will file annual reports under cover of Form 20-F.
Filing Stats: 2,898 words · 12 min read · ~10 pages · Grade level 3.6 · Accepted 2025-09-17 06:16:27
Filing Documents
- a5920z.htm (6-K) — 2446KB
- 0001654954-25-010835.txt ( ) — 2447KB
From the Filing
IN OWN SHARES a5920z   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of September 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .                                       Transaction in own shares   GSK plc (the " Company ") announces today   acting through its corporate stockbroker, Merrill Lynch International (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.     Date of purchase:   16 September 2025   Aggregate number of ordinary shares of  31¼  pence each purchased:   210,377   Lowest price paid per share (GBp):   1,462.00p   Highest price paid per share (GBp):   1,478.00p   Volume-weighted average price paid per share (GBp):   1,468.98p     The purchased shares will be held as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 29,104,717 ordinary shares.   Following the above purchase, the Company will hold 247,239,100 ordinary shares in treasury and have 4,068,163,868 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,068,163,868. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is   6.08 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases   Shares purchased:      GSK plc (ISIN: GB00BN7SWP63)   Date of purchases:     16 September 2025   Investment firm:        Merrill Lynch International     Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share) (GBp)   Lowest price paid (per ordinary share) (GBp)   Volume weighted average price paid (per ordinary share) (GBp)   London Stock Exchange (XLON)   210,377   1,478.00p   1,462.00p   1,468.98p   CBOE (CHIX)   0   -   -   -   CBOE (BATE)   0   -   -   -       Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   38   1,471.00    XLON   16-Sep-2025   08:00:04   0XL06140000000005MJ807   2   1,473.50    XLON   16-Sep-2025   08:00:08   0XL06A00000000005MJ7VM   12   1,473.50    XLON   16-Sep-2025   08:00:13   0XL06A00000000005MJ804   50   1,473.50    XLON   16-Sep-2025   08:00:13   0XL06110000000005MJ82M   52   1,473.50    XLON   16-Sep-2025   08:00:13   0XL06A00000000005MJ805   55   1,473.50    XLON   16-Sep-2025   08:00:13   0XL06D00000000005MJ812   18   1,473.00